Interleukin-1 blockade treatment decreasing cardiovascular risk.

ABSTRACT:

Background

Interleukin-1 (IL-1) played a role in the occurrence and development of atherosclerosis and cardiovascular events. However, the association between IL-1 blockage treatment and reducing of cardiovascular risk remains poorly defined.

Hypothesis

IL-1 blockage treatment reduce the risk and incidence rate of overall major adverse cardiovascular events (MACE), all-cause death, acute myocardial infarction(MI), unstable angina and heart failure.

Methods

We performed a search of published reports by using MEDLINE database (January 1, 2005 to April 1, 2018). The randomized controlled trials (RCTs) that reported sample size and occurrence numbers in test group and placebo group for the associations of interest were included.

Results

Eight RCT studies involving

SUBMITTER: Zheng ZH 

PROVIDER: S-EPMC6788469 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature